Published in Acta Pharmacol Sin on September 17, 2012
The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel) (2014) 1.10
Improving the efficacy of chemoradiation with targeted agents. Cancer Discov (2014) 0.97
HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Akt pathways. Int J Mol Sci (2014) 0.94
Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Mol Cancer (2014) 0.92
Marine lipopeptide Iturin A inhibits Akt mediated GSK3β and FoxO3a signaling and triggers apoptosis in breast cancer. Sci Rep (2015) 0.91
Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications. Eur Arch Otorhinolaryngol (2013) 0.91
Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail. Cell Adh Migr (2015) 0.84
BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt. Br J Cancer (2014) 0.84
Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1 monocytic cell line. J Exp Clin Cancer Res (2013) 0.83
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth. Acta Pharmacol Sin (2013) 0.83
Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ERα status. Oncotarget (2015) 0.78
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism. Oncotarget (2016) 0.78
Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis. Oncotarget (2016) 0.78
A bayesian integrative model for genetical genomics with spatially informed variable selection. Cancer Inform (2014) 0.77
2-(3-Benzoylthioureido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid ameliorates metabolic disorders in high-fat diet-fed mice. Acta Pharmacol Sin (2015) 0.77
RLN2 Is a Positive Regulator of AKT-2-Induced Gene Expression Required for Osteosarcoma Cells Invasion and Chemoresistance. Biomed Res Int (2015) 0.76
Targeting the PI3K signaling pathway in KRAS mutant colon cancer. Cancer Med (2015) 0.76
Neuroblastoma treatment in the post-genomic era. J Biomed Sci (2017) 0.75
Insights into molecular therapy of glioma: current challenges and next generation blueprint. Acta Pharmacol Sin (2017) 0.75
Filamin A interacting protein 1-like expression inhibits progression in colorectal cancer. Oncotarget (2016) 0.75
M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier. Am J Cancer Res (2016) 0.75
Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening. Pharmacogn Mag (2016) 0.75
Induction of apoptosis by Dae-Hwang-Mok-Dan-Tang in HCT-116 colon cancer cells through activation of caspases and inactivation of the phosphatidylinositol 3-kinase/Akt signaling. Integr Med Res (2017) 0.75
Akt2-Dependent Phosphorylation of Radixin in Regulation of Mrp-2 Trafficking in WIF-B Cells. Dig Dis Sci (2016) 0.75
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 21.42
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (1995) 15.15
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 14.36
NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature (1999) 10.48
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (1997) 9.58
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
Phosphoinositide kinases. Annu Rev Biochem (1998) 8.51
NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature (1999) 8.42
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A (1999) 7.70
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 6.65
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev (2001) 6.50
The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal (2002) 6.35
The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol (2010) 6.28
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res (2008) 5.82
PI3K/Akt signalling pathway and cancer. Cancer Treat Rev (2004) 5.46
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res (1999) 4.79
Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 4.74
Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res (2001) 4.73
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res (2001) 4.63
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A (1996) 4.39
A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37
A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J (2001) 3.92
Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta (1998) 3.86
Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J (1999) 3.79
Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem (1999) 3.76
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther (2002) 3.55
Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (2004) 3.47
Akt signalling in health and disease. Cell Signal (2011) 3.42
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42
PTEN: life as a tumor suppressor. Exp Cell Res (2001) 3.41
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A (2009) 3.26
Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol (1996) 3.08
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A (2008) 2.81
Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res (2006) 2.75
The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 2.70
Vascular endothelial growth factor as a target for anticancer therapy. Oncologist (2004) 2.65
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol (2009) 2.43
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther (2009) 2.43
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther (2009) 2.31
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther (2004) 2.25
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther (2003) 2.24
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A (2005) 2.23
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15
The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab (2011) 2.06
PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol (2009) 2.00
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2007) 1.99
Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb Vasc Biol (2003) 1.95
Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl) (2011) 1.87
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther (2011) 1.86
AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res (2007) 1.85
In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst (2010) 1.78
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther (2011) 1.77
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther (2011) 1.76
The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem (2004) 1.75
Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene (2006) 1.72
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 1.70
The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 1.67
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res (2009) 1.64
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2006) 1.62
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood (2010) 1.60
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res (2011) 1.56
GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev (2000) 1.55
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res (2009) 1.54
Insulin receptor and cancer. Endocr Relat Cancer (2011) 1.52
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood (2008) 1.52
Activation of protein kinase B (Akt/RAC-protein kinase) by cellular stress and its association with heat shock protein Hsp27. FEBS Lett (1997) 1.52
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today (2011) 1.52
NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res (2010) 1.52
Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res (2011) 1.48
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev (2010) 1.47
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res (2008) 1.43
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol (2007) 1.41
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41
Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg Med Chem Lett (2007) 1.38
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res (2011) 1.35
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther (2011) 1.33
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther (2007) 1.33
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res (2009) 1.32
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res (2003) 1.32
Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res (1997) 1.30
Regulation of Akt signaling activation by ubiquitination. Cell Cycle (2010) 1.28
The role of IGF-1R in pediatric malignancies. Oncologist (2009) 1.27
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett (2010) 1.27
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol (2010) 1.27
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res (2006) 1.25
A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature (2002) 1.89
Antiproliferative effects of honey and of its polyphenols: a review. J Biomed Biotechnol (2009) 1.89
p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep (2002) 1.30
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res (2004) 1.26
An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res (2005) 1.23
Apoptotic effect of eugenol in human colon cancer cell lines. Cell Biol Int (2011) 1.14
ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther (2010) 1.10
Engineered silk fibroin protein 3D matrices for in vitro tumor model. Biomaterials (2010) 1.09
MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions. J Biol Chem (2003) 1.07
Involvement of non-protein thiols, mitochondrial dysfunction, reactive oxygen species and p53 in honey-induced apoptosis. Invest New Drugs (2009) 1.05
Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma. PLoS One (2012) 1.04
Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther (2005) 1.04
Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One (2013) 1.03
Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors. Cancer Res (2002) 1.02
Silk sericin protein of tropical tasar silkworm inhibits UVB-induced apoptosis in human skin keratinocytes. Mol Cell Biochem (2008) 1.02
Studies on the phenolic profiling, anti-oxidant and cytotoxic activity of Indian honey: in vitro evaluation. Nat Prod Res (2010) 1.01
Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer (2013) 1.00
The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials (2011) 0.99
Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope (2007) 0.99
Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther (2003) 0.98
Identification and structural insights of three novel antimicrobial peptides isolated from green coconut water. Peptides (2008) 0.98
Effect of honey and eugenol on Ehrlich ascites and solid carcinoma. J Biomed Biotechnol (2010) 0.97
Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol (2010) 0.97
Antitumor promoting potential of selected phytochemicals derived from spices: a review. Eur J Cancer Prev (2012) 0.96
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. J Cell Physiol (2011) 0.96
Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol (2009) 0.96
Molecular analysis of anoikis resistance in oral cavity squamous cell carcinoma. Oral Oncol (2006) 0.94
Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res (2005) 0.93
Effective bacterial inactivation using low temperature radio frequency plasma. Int J Pharm (2010) 0.91
Autophagy: cancer's friend or foe? Adv Cancer Res (2013) 0.89
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther (2005) 0.88
Events associated with apoptotic effect of p-Coumaric acid in HCT-15 colon cancer cells. World J Gastroenterol (2013) 0.87
Second generation liposomal cancer therapeutics: transition from laboratory to clinic. Int J Pharm (2013) 0.87
Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention. Eur J Cancer Prev (2014) 0.85
Identification and characterization of a bactericidal and proapoptotic peptide from Cycas revoluta seeds with DNA binding properties. J Cell Biochem (2012) 0.84
Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11. Head Neck (2006) 0.84
Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol (2011) 0.83
Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques. Micron (2009) 0.83
Effect of Mangiferin and Mahanimbine on Glucose Utilization in 3T3-L1 cells. Pharmacogn Mag (2013) 0.83
Molecular targeting of Akt by thymoquinone promotes G(1) arrest through translation inhibition of cyclin D1 and induces apoptosis in breast cancer cells. Life Sci (2013) 0.82
Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer. Breast Cancer (Auckl) (2009) 0.82
Stimulation of indoleacetic acid production in a Rhizobium isolate of Vigna mungo by root nodule phenolic acids. Arch Microbiol (2009) 0.81
AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells. Life Sci (2012) 0.81
Photoresponsive coumarin-tethered multifunctional magnetic nanoparticles for release of anticancer drug. ACS Appl Mater Interfaces (2013) 0.79
Thymoquinone restores radiation-induced TGF-β expression and abrogates EMT in chemoradiotherapy of breast cancer cells. J Cell Physiol (2015) 0.78
PKI 166 induced redox signalling and apoptosis through activation of p53, MAP kinase and caspase pathway in epidermoid carcinoma. J Exp Ther Oncol (2012) 0.78
Comparative analyses of different surfactants on matrix-assisted laser desorption/ionization mass spectrometry peptide analysis. Eur J Mass Spectrom (Chichester, Eng) (2010) 0.78
Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model. Cancer Biol Ther (2015) 0.77
Induction of apoptosis of azurin synthesized from P. aeruginosa MTCC 2453 against Dalton's lymphoma ascites model. Biomed Pharmacother (2011) 0.77
Heregulin promotes expression and subcellular redistribution of ADP-ribosylation factor 3. FEBS Lett (2002) 0.77
Proteomics view of a Rhizobium isolate response to arsenite [As(III)] stress. Acta Microbiol Immunol Hung (2009) 0.76
Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes. Mol Pharm (2015) 0.76
Insights into molecular therapy of glioma: current challenges and next generation blueprint. Acta Pharmacol Sin (2017) 0.75
Micellear Gold nanoparticle as delivery vehicle for dual tyrosine kinase inhibitor ZD6474 for metastatic breast cancer treatment. Langmuir (2017) 0.75
Rapid determination of vitamin B2 and B12 in human urine by isocratic liquid chromatography. Anal Chim Acta (2009) 0.75
Amino acid based amphiphilic copolymer micelles as carriers of non-steroidal anti-inflammatory drugs: solubilization, in vitro release and biological evaluation. Int J Pharm (2011) 0.75
Iron oxide nanoparticle assisted purification and mass spectrometry based proteolytic mapping of intact CD4+ T cells from human blood. Prep Biochem Biotechnol (2009) 0.75
Probabilistic graphical modeling of speckle statistics in laser speckle contrast imaging for noninvasive and label-free retinal angiography. Conf Proc IEEE Eng Med Biol Soc (2015) 0.75